Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Blood·2014

Same author

Daratumumab granted breakthrough drug status.

Expert opinion on investigational drugs·2014

Same author

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

International journal of oncology·2014

Same author

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Blood·2014

Same author

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Nature communications·2014

Same author

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014

Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026

Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026

Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026

Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026

Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026

Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Vision Statement for Multiple Myeloma: Future Directions.

Kenneth C Anderson¹

¹Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. kenneth_anderson@dfci.harvard.edu.

Cancer Treatment and Research

|October 4, 2016

Summary

This summary is machine-generated.

Novel therapies targeting multiple myeloma vulnerabilities are urgently needed. Targeting protein degradation, immune response, and DNA damage early could transform myeloma into a chronic, curable disease.

Keywords:

Immune therapies Multiple myeloma Protein degradation Targetted therapies

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: Mar 14, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

Hematology
Oncology
Immunology

Background:

Significant advancements in multiple myeloma management have been achieved with novel agents like immunomodulatory drugs and proteasome inhibitors.
Despite progress, there remains an urgent need for new therapeutic strategies to further improve patient outcomes.

Purpose of the Study:

To identify and discuss three key vulnerabilities in multiple myeloma for novel therapeutic targeting.
To explore the potential of early intervention in smouldering multiple myeloma to alter disease trajectory.

Main Methods:

Review of current therapeutic landscape and identification of emerging targets in multiple myeloma.
Analysis of biological pathways including protein degradation (ubiquitin-proteasome and aggresome), autologous immunity, and DNA damage response in myeloma cells.

Main Results:

Three critical vulnerabilities identified: 1) protein degradation pathways, 2) restoration of antimyeloma immunity, and 3) targeting aberrant biology from DNA damage.
Early application of therapies targeting these vulnerabilities, particularly in smouldering multiple myeloma, shows promise.

Conclusions:

Targeting these specific vulnerabilities offers a promising avenue for novel multiple myeloma therapies.
Early therapeutic intervention has the potential to significantly alter the natural history of multiple myeloma, potentially leading to a chronic and curable disease state.